August 23, 2023
Exclusive: Bloomberg Technology’s Ed Ludlow Interviews Cellares’ CEO and Co-founder, Fabian Gerlinghaus on Company’s Massive $255M Series C Up-Round
Related News
-
May 11, 2026Cellares and ProTgen Partner to Automate Manufacturing for ProT-096, a Novel Progenitor T Cell Therapy Designed to Restore Immune Competence
-
April 28, 2026
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
-
April 14, 2026
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform
